Summary of Task Force suggestions#
| The Task Force made the following consensus suggestions |
| For hospitalised patients with COVID-19 pneumonia who require supplemental oxygen but are not mechanically ventilated, the Task Force suggests remdesivir: |
| 86% suggest remdesivir, 11% make no suggestion for or against remdesivir, and 3% suggest not using remdesivir |
| For hospitalised patients with COVID-19 pneumonia who are mechanically ventilated, the Task Force suggests remdesivir: |
| 77% suggest remdesivir, 16% make no suggestion for or against remdesivir, and 7% suggest not using remdesivir |
| For hospitalised patients with COVID-19 pneumonia who require supplemental oxygen but are not mechanically ventilated, the Task Force suggests dexamethasone: |
| 84% suggest dexamethasone, 13% make no suggestion for or against dexamethasone, and 3% suggest not using dexamethasone |
| For hospitalised patients with COVID-19 pneumonia who are mechanically ventilated, the Task Force suggests dexamethasone: |
| 96% suggest dexamethasone, 1% make no suggestion for or against dexamethasone, and 3% suggest not using dexamethasone |
| For adults who were hospitalised with COVID-19 pneumonia and had confirmed venous thromboembolism, the Task Force suggests therapeutic anticoagulant therapy for 3 months to reduce the risk of recurrent venous thromboembolism: |
| 95% favour therapeutic anticoagulant therapy for 3 months, 1% favour therapeutic anticoagulant therapy for >3 months, and 4% make no suggestion for either approach |
| For hospitalised patients with COVID-19 pneumonia who require supplemental oxygen but are not mechanically ventilated, the Task Force suggests not using HCQ except within a clinical trial: |
| 3% suggest HCQ, 9% make no suggestion for or against HCQ, and 88% suggest not using HCQ |
| For hospitalised patients with COVID-19 pneumonia who are mechanically ventilated, the Task Force suggests not using HCQ except within a clinical trial: |
| 0% suggest HCQ, 9% make no suggestion for or against HCQ, and 91% suggest not using HCQ |
COVID-19: coronavirus disease 2019; HCQ: hydroxychloroquine. #: >70% agreement among Task Force members.